Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(3):157; doi:10.1093/jnci/97.3.157
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Japanese Translation
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

IN THIS ISSUE

IN THIS ISSUE

The first 10% of the full text of this article appears below.

Neoadjuvant Versus Adjuvant Treatment for Breast Cancer

Neoadjuvant therapy for breast cancer appears to reduce the extent of local surgery. To evaluate whether neoadjuvant therapy also affects disease progression end points, Mauri et al. (p. 188) conducted a meta-analysis of randomized trials that compared the clinical end points of patients treated with neoadjuvant therapy and patients treated with the same regimen given as adjuvant therapy. They found no statistically significant difference between the neoadjuvant and adjuvant therapy arms in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with an increased risk of locoregional . . . [Full Text of this Article]

Sun Exposure and Cancer Risk

Inadequate Lymph Node Evaluation in Colorectal Cancer

Body Mass Index and Risk of Malignant Lymphoma

Imaging Angiogenesis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?